Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 14/20 | 0.50 |
| ▸ | RARA | P10276 | 14/20 | 0.50 |
| ▸ | RARG | P13631 | 13/20 | 0.50 |
| ▸ | RXRA | P19793 | 5/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 2/20 | 0.39 |
| ▸ | RXRG | P48443 | 2/20 | 0.39 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26304518 | 1.00 | RARB (0.50) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL26304521 | 1.00 | RARB (0.50) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL26304689 | 0.96 | RARB (0.50) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL26304842 | 0.96 | RARB (0.50) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL26305028 | 0.96 | RARB (0.45) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL26308239 | 0.96 | RARB (0.45) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL26303481 | 0.96 | RARB (0.45) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL26303484 | 0.96 | RARB (0.45) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL29331095 | 0.96 | RARB (0.45) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL26304674 | 0.96 | RARB (0.54) | RARBRARARARGRXRACYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12048240-B2 | Organic compound, electronic component and electronic apparatus comprising the same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2024-07-23 | — | — | US | disclosed |
| US-12048240-B2 | Organic compound, electronic component and electronic apparatus comprising the same | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2024-07-23 | — | — | US | disclosed |
| WO-2023160121-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT COMPRISING SAME, AND ELECTRONIC DEVICE | 陕西莱特光电材料股份有限公司 | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12048240-B2 | Organic compound, electronic component and electronic apparatus comprising the same | PIEZO1, OCIAD1, OSTC | RARB 2554/4885RARA 1944/4885RARG 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.